Advertisement

Chemotherapy in Prostatic Cancer

  • Joseph R. Drago
  • Jack S. Elder
Part of the Cancer Treatment and Research book series (CTAR, volume 19)

Abstract

Prostatic cancer is the third leading cause of cancer deaths in the United States, accounting for approximately 20 000 deaths per year[l].

Keywords

Prostatic Cancer Objective Response Objective Response Rate Advanced Prostatic Cancer Subjective Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Williams SD, Einhorn LH: Prostate cancer: The current approach to diagnosis and treatment. Chicago: Bristol Laboratories, 1980.Google Scholar
  2. 2.
    Coffey DS et al.: Prostate tumor biology and cell kinetics — theory. Urology (Suppl) 17(3):40–53, 1981.Google Scholar
  3. 3.
    Gibbons RP: Cooperative clinical trial of single and combined agents protocols: Adjuvant protocols. Urology (Suppl) 17(4):48–52, 1981.Google Scholar
  4. 4.
    Schmidt JD, Gibbons RP, Johnson DE et al.: Chemotherapy of advanced prostatic cancer: Evaluation of response parameters. Urology 7:602–610, 1976.PubMedCrossRefGoogle Scholar
  5. 5.
    Kiely JM: Clinical pharmacology: 12. Antineoplastic agents. Mayo Clin Proc 56:384–392, 1981.PubMedGoogle Scholar
  6. 6.
    Goodman LS, Gilman A: The Pharmacological Basis of Therapeutics, 5th ed. New York: MacMillan Publishing Co, 1975.Google Scholar
  7. 7.
    Scott WW, Johnson DE, Schmidt JE et al.: Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-Fu: Results of first national randomized study. J Urol 114:909–911, 1975.PubMedGoogle Scholar
  8. 8.
    Blum RH, Carter SK: Adriamycin: A new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259, 1974.PubMedGoogle Scholar
  9. 9.
    Adamson RH: Daunomycin (NSC-82151) and Adriamycin (NSC-123127). An hypothesis concerning antitumor activity and cardiotoxicity (Letter to the editor). Cancer Chemother Rep 58:293–294, 1974.PubMedGoogle Scholar
  10. 10.
    Rinehart JJ, Lewis RP, Bakerzak SP: Adriamycin cardiotoxicity in man. Ann Intern Med 81:475–478, 1974.PubMedGoogle Scholar
  11. 11.
    Herr HW: Cyclophosphamide, methotrexate, and 5-Fu. Combination chemotherapy vs. chloroethylcyclohexynitrosourea in the treatment of metastatic prostate cancer. J Urol 127:462–465, 1982.PubMedGoogle Scholar
  12. 12.
    Bleyer WA: Methotrexate: Clinical pharmacology, current status, and therapeutic guidelines. Cancer Treat Rev 4:87–101, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Bleyer WA: The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 41:36–51, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Skarin AT, Zuckerman KS, Pittman SW, Rosenthal DS, Moloney W, Frei E, III, Canelos GP: High dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50:1039–1047, 1977.PubMedGoogle Scholar
  15. 15.
    Slack NH, Brady MF, Murphy GP: Observations of prolonged use of oral Emcyt in prostatic cancer patients. Urology 20(5):515–523, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Smalley RV, Bartolucci AA et al.: A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125:191–195, 1981.PubMedGoogle Scholar
  17. 17.
    Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP: The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116:211–213, 1976.PubMedGoogle Scholar
  18. 18.
    Chlebowski RT, HestorffR, Sardoff L, Weiner J, Bateman JR: Cyclophosphamide (NSC-26271) vs. the combination of adriamycin (NSC-123127), 5-fluorouracil (NSC-19893), and cyclophosphamide in the treatment of metastatic prostate Ca. Cancer 42:2546–2552, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Eagan RT, Hahn RG, Myers PP: Adriamycin vs. 5-Fu and cyclophosphamide in the treatment of metastatic prostate cancer. Cancer Treat Rep 60:115–117, 1976.PubMedGoogle Scholar
  20. 20.
    Collier D, Soloway MS: Doxorubicin hydrochloride, cyclophosphamide, and 5-Fu combination in advanced prostate and transitional cell carcinoma. Urology 8:459–464, 1976.PubMedCrossRefGoogle Scholar
  21. 21.
    Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G: Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J Urol 115:86–88, 1976.PubMedGoogle Scholar
  22. 22.
    White R, Babaian RK, Feldman M, Krane RJ, Olsson CA: Adjunctive therapy with interstitial irradiation for prostate cancer. Urology 19(4):395–398, 1982.CrossRefGoogle Scholar
  23. 23.
    Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR Jr, Loening SA, Soloway MS, Chu TM, Gaeta JF, Slack NH, Saroff J, Murphy GP: Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121:185–189, 1979.PubMedGoogle Scholar
  24. 24.
    Loening SA, Scott WW, DeKeraion J, Gibbons RP, Johnson DE, Pontes JE, Prout GR, Schmidt JD, Soloway MS, Chu TM, Gaeta JR, Slack NH, Murphy GP: A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamode in patients with advanced carcinoma of the prostate. J Urol 125:812–816, 1981.PubMedGoogle Scholar
  25. 25.
    Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL: Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: A randomized trial. Cancer 47:1949–1953, 1981.PubMedCrossRefGoogle Scholar
  26. 26.
    Carter SK, Wasserman TH: The chemotherapy or urologic cancer. Cancer 36:729–747, 1975.PubMedCrossRefGoogle Scholar
  27. 27.
    Neuin JE, Hoffman AA: Use of arterial infusion of 5-Fu either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. Am J Surg 130:544–549, 1975.CrossRefGoogle Scholar
  28. 28.
    Neuin JE, Melnick I, Baggerly JT Jr, Hoffman A, Landes RR, Easly C: The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of advanced carcinoma of the bladder and prostate: A preliminary report. Cancer 31:138–144, 1973.CrossRefGoogle Scholar
  29. 29.
    Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Chu TM, Gaeta JF, Joiner J, Saroff J, Murphy GP: Comparison of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in patients with advanced carcinoma of the prostate. Cancer Chemother Rep 59:195–201, 1975.Google Scholar
  30. 30.
    DeWys WD, Bauer M, Colsky J, Cooper RA, Creech R, Carbone PP: Comparative trial of adriamycin and 5-Fu in advanced prostatic cancer — progress report. Cancer Treat Rep 61:325–328, 1977.PubMedGoogle Scholar
  31. 31.
    Benson RC, Ward JB, Gill GM: Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate. J Urol 121:452–454, 1979.PubMedGoogle Scholar
  32. 32.
    Kuss R, Khoury S, Richard F, Fourcade R, Frantz P, Capelle JP: Estrogen-resistant prostate cancer with osseous metastasis: Pallative chemotherapy by 5-fluorouracil and cyclophosphamide. Nouv Presse Med 7:24–78, 1978.Google Scholar
  33. 33.
    Soloway MS, DeKernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, Proute GR, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP: Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125:664–667, 1981.PubMedGoogle Scholar
  34. 34.
    Schmidt J: Chemotherapy of hormone-resistant stage D prostatic cancer. J Urol 123:797–805, 1980.PubMedGoogle Scholar
  35. 35.
    Murphy GP, Saroff J, Joiner JR, Prout GR, Gibbons RP, Schmidt JD, Johnson DE, Scott WW: Chemotherapy of advanced prostatic cancer by the National Prostatic Cancer Group. Semin Oncol 3(2):103–106, 1976.PubMedGoogle Scholar
  36. 36.
    Slack NH, Wajsman Z, Mittelman A, Bruno S, Murphy GP: Relationship of prior hormonal therapy to subsequent estramustine phosphate treatment in advanced prostatic cancer. Urology 14:549–554, 1979.PubMedCrossRefGoogle Scholar
  37. 37.
    Kuss R, Khoury S, Richard F, Fourcade F, Frantz P, Capelle JP: Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52:29–33, 1980.PubMedCrossRefGoogle Scholar
  38. 38.
    Ihde DC, Bunn PA, Cohen MH, Dunnock NR, Eddy JL, Minna JD: Effective treatment of hormonally unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Cancer 45:1300–1310, 1980.PubMedCrossRefGoogle Scholar
  39. 39.
    Mukamel E, Nissenkorn I, Servadio C: Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology 16(3):257–260, 1980.PubMedCrossRefGoogle Scholar
  40. 40.
    Kane RD, Stocks LH, Paulson DF: Multiple drug chemotherapy regimen for patients with hormonally unresponsive carcinoma of the prostate: A preliminary report. J Urol 117:467–471, 1977.PubMedGoogle Scholar
  41. 41.
    O’Bryan RM, Baker LH, Gottlieb JE, Balcerzak SP, Grumet GN, Salmon SC, Moon TE, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948, 1977.PubMedCrossRefGoogle Scholar
  42. 42.
    DeWys WD: Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-019893) in advanced prostatic cancer. Cancer Chemother Rep 59:215–217, 1975.PubMedGoogle Scholar
  43. 43.
    Paulson DF, Walker RA, Berry WR, Cox EB, Hinshaw W: Vincristine, belomycin, methotrexate, 5-Fu and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma. Urology 17(5):443–445, 1981.PubMedCrossRefGoogle Scholar
  44. 44.
    Fossa SD, Miller A: Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115:406–408, 1976.PubMedGoogle Scholar
  45. 45.
    Mittleman A, Shukla SK, Murphy GP: Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J Urol 115:409–412, 1976.Google Scholar
  46. 46.
    Chisholm GD, O’Donoghue PN, Kennedy CL: The treatment of oestrogen-escaped carcinoma of the prostate with estramustine phosphate. Br J Urol 49:717–720, 1977.PubMedCrossRefGoogle Scholar
  47. 47.
    Von Hoff DD, Rozencweig M, Slavik M, Muggia FM: Estramustine phosphate: A specific therapeutic agent? J Urol 177:464–466, 1977.Google Scholar
  48. 48.
    Merrin C: Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedichloroplatinum (II NSC-119875): A pilot study. J Urol 119:522–524, 1978.PubMedGoogle Scholar
  49. 49.
    Merrin CE, Beckley S: The treatment of estrogen-resistant stage D carcinoma of the prostate with cis-diamminedichloroplatinum. Urology 13:267–272, 1979.PubMedCrossRefGoogle Scholar
  50. 50.
    Beckley S, Wajsman Z, Maeso E, Pontes E, Murphy G: Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. Urology 18(6):592–595, 1981.PubMedCrossRefGoogle Scholar
  51. 51.
    Houghton AL, Robinson MR, Smith PH: Melphalan in advanced prostatic cancer: A pilot study. Cancer Treat Rep 61:923–925, 1977.PubMedGoogle Scholar
  52. 52.
    Torti FM, Carter SK: The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 92:681–689, 1980.PubMedGoogle Scholar
  53. 53.
    Spector RE: Chemotherapy of prostatic cancer. J Iowa Med Soc 6:168–172, 1978.Google Scholar
  54. 54.
    Veronesi A, Zattoni F, Frustaci S, Gallagioni E, Tirelli U, Trovo G, Tumolo S, Merlo A, Artuso G, Cosciani-Cunico S, Grigoletto E: Estramustine phosphate (Estracyt ®) treatment of T3-T4 prostatic cancer. Prostate 3:159–164, 1982.PubMedCrossRefGoogle Scholar
  55. 55.
    Citrin DL, Cohen AI, Harberg J, Schlise S, Hougen C, Benson R: Systemic treatment of advanced prostatic cancer: Development of a new system for defining responses. J Urol 125:224–227, 1981.PubMedGoogle Scholar
  56. 56.
    Yagoda A, Watson RC, Natale RB, Burzell W, Sogani P, Grabstald H, Whitmore WF: A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 44:1553–1562, 1979.PubMedCrossRefGoogle Scholar
  57. 57.
    Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR, Loening S, Soloway M, DeKernion J, Pontes JE, Slack NH, Murphy GP: Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer 45:1937–1946, 1980.PubMedGoogle Scholar
  58. 58.
    Rossof AH, Talley RW, Stephens R et al.: Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group Study. Cancer Treat Rep 63:1557–1564, 1979.PubMedGoogle Scholar
  59. 59.
    Soloway MS, Tidwell M: Cytoxan, adriamycin and 5-fluorouracil combination chemotherapy in advanced cancer of the prostate. Proc Am Assoc Cancer Res 18:2–9, 1977.Google Scholar
  60. 60.
    Strauss MJ, Parmelee J, Olsson C, DeVere R, White R: Cytoxan, adriamycin, methotrexate (CAM) therapy of stage D prostate cancer. Proc Am Soc Clin Oncol 19:314–318, 1978.Google Scholar
  61. 61.
    Perloff M, Ohnuma T, Holland JF et al.: Adriamycin (ADM) and diamminedichloroplatinum (DDP) in advanced prostatic carcinoma (PC). Proc Am Soc Clin Oncol 18:333–337, 1977.Google Scholar
  62. 62.
    DeWys WD, Bogg CG: Comparison of adiramycin (ADRIA) and 5-fluorouracil (5-Fu) in advanced prostatic cancer. Proc Am Soc Clin Oncol 19:331–332, 1977.Google Scholar
  63. 63.
    Lerner HJ, Malloy TR: Hydroxyurea in stage D carcinoma of prostate. Urology 10:35–38, 1977.PubMedCrossRefGoogle Scholar
  64. 64.
    Catane R, Kaufman JH, Magajewicz S, Mittleman A, Murphy GP: Prednimustine therapy for advanced prostatic carcinoma. Br J Urol 50:29–32, 1978.PubMedCrossRefGoogle Scholar
  65. 65.
    Murphy GP, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Soloway MS, Loening SA, Chu TM, Gaeta JF, Saroff J, Wajsman Z, Slack N, Scott WW: The use of estramustine and prednimustine versis prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. J Urol 121:763–766, 1977.Google Scholar
  66. 66.
    Tejada F, Eisenberger MA, Broder LA, Cohen MH, Simon R: 5-Fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treat Rep 61:1589–1590, 1977.PubMedGoogle Scholar
  67. 67.
    Slack NH et al.: Prednimustine for prostate cancer therapy. Compr Ther 5(9): 54–57, 1979.PubMedGoogle Scholar
  68. 68.
    Lerner H, Malloy T, Cromie W et al.: Hydroxyurea in stage D carcinoma of the prostate: A pilot study. J Urol 114:425–429, 1975.PubMedGoogle Scholar
  69. 69.
    Fang S, Liao S: Antagonistic action of anti-androgens on the formation of a specific dihydrotestosterone-receptor protein complex in rat ventral prostate. Mol Pharmacol 5:428–432, 1969.PubMedGoogle Scholar
  70. 70.
    Walsh PC, Korenman SG: Mechanism of androgenic action: Effect of specific intracellular inhibitors. J Urol 105:850–854, 1971.PubMedGoogle Scholar
  71. 71.
    Neri R, Florance K, Koziol P et al.: A biological profile of a non-steroidal antiandrogen SCH 13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 93:427–428, 1972.CrossRefGoogle Scholar
  72. 72.
    Smith RB, Walsh PC, Goodwin WE: Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J Urol 110:106–111, 1973.PubMedGoogle Scholar
  73. 73.
    Geller J, Vazakas G, Fruchtman B et al.: The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg Gynecol Obstet 127:748–753, 1968.PubMedGoogle Scholar
  74. 74.
    Stoliar B, Albert DJ: SCH 13521 in the treatment of advanced carcinoma of the prostate. Urology 111:803–807, 1974.Google Scholar
  75. 75.
    Resnick MI, Grayhack JT: Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 2:141–160, 1975.PubMedGoogle Scholar
  76. 76.
    Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–549, 1981.PubMedCrossRefGoogle Scholar
  77. 77.
    Santen RJ, Worgul TJ, Harvey H, Lipton A, Smart E, Boucher A, White D, Wells S: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma: Correlation of clinical and hormonal responses. Ann Intern Med (in press).Google Scholar
  78. 78.
    Sanford EJ, Drago JR, Rohner TJ Jr, Santen R, Lipton A: Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol 115:170–174, 1976.PubMedGoogle Scholar
  79. 79.
    Worgul TJ, Santen RJ, Samojlik E, Veldhuis JD, Lipton A, Harvey HA, Drago JR, Rohner TJ: The clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol (in press).Google Scholar
  80. 80.
    Noble RL: Tumors and hormones. In: Hormones, Pincus G (ed). New York: Academic Press, Vol 5, pp 559–579, 1964.Google Scholar
  81. 81.
    Pollard N, Luckert PH: Transplantable metastasizing prostate adenocarcinomas in rats. J Natl Cancer Inst 54:643–649, 1975.PubMedGoogle Scholar
  82. 82.
    Smolev KJ, Heston W, Scott WW et al.: Characterization of the Dunning R3327H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer. Cancer Treat Rep 61:273–287, 1977.PubMedGoogle Scholar
  83. 83.
    Drago JR, Ikeda RM, Maurer RE, Goldman LB, Tesluk H: The Nb rat: Prostatic adenocarcinoma model. Invest Urol 16(5): 353–359, 1979.PubMedGoogle Scholar
  84. 84.
    Shain SA, Boesel RW, Axelrod LA: Aging in the rat prostate. Reduction in detectable ventral prostate androgen receptor content. Arch Biochem Biophys 167:247–263, 1975.PubMedCrossRefGoogle Scholar
  85. 85.
    Drago JR, Goldman LB, Gershwin ME: Chemotherapeutic and hormonal considerations of the Nb rat prostatic adenocarcinoma model. In: Models for Prostatic Cancer. New York: Alan R Liss, Inc, pp 325–363, 1980.Google Scholar
  86. 86.
    Murphy GP et al.: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones, versus hormones alone. Cancer 51:86–94, 1983.CrossRefGoogle Scholar
  87. 1.
    Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE: Doxorubicin, mitomycin, and 5-Fu (DMF) in the treatment of hormone-resistant stage D prostate cancer: A preliminary report. Cancer Treat Rep 66:57–63, 1982.PubMedGoogle Scholar
  88. 2.
    Silverberg E: Cancer statistics. CA 32:15–31, 1982.PubMedGoogle Scholar
  89. 3.
    Murphy GP: Prostate cancer today. Urology 17 (March Suppl):1–3, 1981.PubMedCrossRefGoogle Scholar
  90. 4.
    Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011–1017, 1967.Google Scholar
  91. 5.
    Gibbons RP, Mason JT, Correa RJ, Cumming KB, Taylor WJ, Hafermann MD, Richardson RG: Carcinoma of the prostate: Local control with external beam radiation therapy. J Urol 121:310–312, 1979.PubMedGoogle Scholar
  92. 6.
    Tomlinson RL, Currie DP, Boyce WH: Radical prostatectomy: Palliation for stage C carcinoma of the prostate. J Urol 117:85–87, 1977.PubMedGoogle Scholar
  93. 7.
    Huggins C, Stevens RE, Hodges CV: Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223, 1941.Google Scholar
  94. 8.
    Menon M, Catalona WJ: Interpreting response to treatment and advanced prostatic cancer. Rev Endocrine-Related Cancer 10:11–17, 1981.Google Scholar
  95. 9.
    Schmidt JD: Chemotherapy of hormone-resistant stage D prostatic cancer. J Urol 123:797–805, 1980.PubMedGoogle Scholar
  96. 10.
    Yagoda A: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma. Cancer 32:1131–1140, 1973.PubMedCrossRefGoogle Scholar
  97. 11.
    Weissman RM, Coffey DS, Scott WW: Cell kinetic studies of prostatic cancer: Adjuvant therapy in animal models. Oncology 34:133–137, 1977.PubMedCrossRefGoogle Scholar
  98. 12.
    Drago JR, Ikeda RM, Maurer RE, Goldman LB, Tesluk H: The Nb rat prostatic adenocarcinoma model. Invest Urol 16:353–359, 1979.PubMedGoogle Scholar
  99. 13.
    Soloway MS, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Murphy GP: A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J Urol 129:56–61, 1983.PubMedGoogle Scholar
  100. 14.
    Loening SA, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy JP: Comparison of estramustine phosphate (Emcyt), methotrexate, and cis-platinum in patients with advanced, hormone-refractory prostate cancer. J Urol 129:1001–1006, 1983.PubMedGoogle Scholar
  101. 15.
    Goldie JH: New thoughts on resistance to chemotherapy. Hosp Pract 18(May):165–177, 1983.Google Scholar
  102. 16.
    Drewinko B, Humphrey RM (eds): Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells. Baltimore: Williams and Wilkins Company, 1977.Google Scholar
  103. 17.
    Skipper HE: Thoughts on cancer chemotherapy and combination modelity therapy. JAMA 230:1033–1035, 1975.CrossRefGoogle Scholar
  104. 18.
    Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW: Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54:431–450, 1970.PubMedGoogle Scholar
  105. 19.
    Coffey DS, Isaacs JT: Prostate tumor biology and cell kinetics — theory. Urology 17(March suppl):40–53, 1981.PubMedGoogle Scholar
  106. 20.
    Charbit A, Malaise E, Tubiana M: Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer 7:307–315, 1971.PubMedGoogle Scholar
  107. 21.
    Smolev J, Heston W, Scott W, Coffey D: Characterization of the Dunning R-3327-H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer. Cancer Treat Rep 61:273–287, 1977.PubMedGoogle Scholar
  108. 22.
    Tannock IF: Biology of tumor growth. Hosp Pract 18(April):81–93, 1983.Google Scholar
  109. 23.
    Tubiana M, Malaise EP: Growth rate and cell kinetics in human tumors. In: Scientific Formulations of Oncology, Symington T, Carter RL (eds). Chicago: Yearbook Medical Publishers, pp 126–136, 1976.Google Scholar
  110. 24.
    Elliott EM, Ling V: Selection and characterization of Chinese hamster ovary cell mutants resistant to melphalan (L-phenylalanine mustard). Cancer Res 41:393–400, 1981.PubMedGoogle Scholar
  111. 25.
    Smolev JK, Coffey DS, Scott WW: Experimental models for the study of prostatic adenocarcinoma. J Urol 118:217–220, 1977.Google Scholar
  112. 26.
    Jordan WP Jr, Blackard CE, Byar DP: Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70:1411–1413, 1977.PubMedGoogle Scholar
  113. 27.
    Reiner WG, Scott WW, Eggleston JC, Walsh PC: Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol 122:183–184, 1979.PubMedGoogle Scholar
  114. 28.
    Trachtenberg J, Walsh PC: Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466–471, 1982.PubMedGoogle Scholar
  115. 29.
    Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffey DS: A new method to assess metastatic potential of human prostatic cancer: Relative nuclear roundness. J Urol 128:729–734, 1982.PubMedGoogle Scholar
  116. 30.
    Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS: Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 3:321–332, 1982.PubMedCrossRefGoogle Scholar
  117. 31.
    Murphy GP, Beckley S, Chu TM, deKernion JB, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pierce JM, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264–1272, 1983.PubMedCrossRefGoogle Scholar
  118. 32.
    Torti FM, Carter SK: The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 92:681–689, 1980.PubMedGoogle Scholar
  119. 33.
    Grayhack JT, Kozlowski JN: Endocrine therapy in the management of advanced prostatic cancer: The case for early initiation of treatment. Urol Clin North Am 7:639–643, 1980.PubMedGoogle Scholar
  120. 34.
    Slack NH, Mittelman A, Brady MF, Murphy GP, Investigators in the National Prostatic Cancer Project: The importance of the stable category for chemotherapy-treated patients with advanced and relapsing prostate cancer. Cancer 46:2393–2402, 1980.PubMedCrossRefGoogle Scholar
  121. 35.
    Elder JS, Catalona WJ: Management of newly diagnosed metastatic carcinoma of the prostate. Urol Clin North Am (in press).Google Scholar
  122. 36.
    Fossa SD, Miller A: Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115:406–408, 1976.PubMedGoogle Scholar
  123. 37.
    Nilsson T, Jonsson G: Primary treatment of prostatic carcinoma with estramustine phosphate: a preliminary report. J Urol 115:168–169, 1976.PubMedGoogle Scholar
  124. 38.
    Merrin CE: Treatment of previously untreated (by hormonal manipulation) stage D adenocarcinoma of prostate with combined orchiectomy, estrogen, and cis-diamminedichloroplatinum. Urology 15:123–126, 1980.PubMedCrossRefGoogle Scholar
  125. 39.
    Beckley S, Wajsman Z, Maeso E et al.: Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. Urology 18:592–595, 1981.PubMedCrossRefGoogle Scholar
  126. 40.
    Smith PH: Endocrine and cytotoxic therapy. Rec Res Cancer Res 78:154–172, 1981.Google Scholar
  127. 41.
    Benson RC Jr, Gill GM, Cummings KB: A randomized double-blind cross-over trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostate carcinoma. Am Urol Assoc (Abstract). Kansas City, Missouri, p 152, 1982.Google Scholar
  128. 42.
    Servadio C, Mukamel E, Lurie H, Nissenkora I: Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology 21:493–495, 1983.PubMedCrossRefGoogle Scholar
  129. 43.
    Kramer SA, Cline WA Jr, Farnham R, Carson CC, Cox EB, Hinshaw W, Paulson DC: Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 125:817–819, 1981.PubMedGoogle Scholar
  130. 44.
    Paulson DF, Cline WA Jr, Coefoot RB Jr, Hinshaw W, Stephani S, Uro-Oncology Research Group: Extended field radiation therapy versus delayed hormonal therapy in node-positive prostatic adenocarcinoma. J Urol 127:935–937, 1982.PubMedGoogle Scholar
  131. 45.
    Zincke H, Fleming TR, Furlow WL, Myers RP, Utz BC: Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer 47:1901–1910, 1981.PubMedCrossRefGoogle Scholar
  132. 46.
    deVere White R, Babaian RK, Feldman M, Krane RJ, Olsson CA: Adjunctive therapy with interstitial irradiation for prostate cancer. Urology 19:395–398, 1982.PubMedCrossRefGoogle Scholar
  133. 47.
    Scardino PT, Lehane DE: Intermittent arterial infusion chemotherapy for advanced, hormonally risistant, radiorecurrent carcinoma of the prostate. Amurol Assoc (Abstract # 222). Kansas City, p 113, 1982.Google Scholar
  134. 48.
    Nevin JE, Hoffman AA: Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. Am J Surg 130:544–549, 1975.PubMedCrossRefGoogle Scholar
  135. 49.
    Lytton B, Collins JT, Weiss RM, Schiff M Jr, McGuire EJ, Livolsi V: Results of biopsy after early stage prostatic cancer treatment by implantation of 125I seeds. J Urol 121:306–309, 1979.PubMedGoogle Scholar
  136. 50.
    Wheeler TM, Scardino PT: Detailed pathologic review of prostate biopsy following irradiation for carcinoma of the prostate. Am Urol Assoc Annu Meeting (Abstract # 298). Las Vegas, p 166, 1983.Google Scholar
  137. 51.
    Elder JS, Gibbons RP: Surgery for localized and disseminated cancer of the prostate. Clin Oncol 2:421–440, 1983.Google Scholar
  138. 52.
    Walsh PC, Jewett HJ: Radical surgery for prostatic cancer. Cancer 45:1906–1911, 1980.PubMedGoogle Scholar
  139. 53.
    Elder JS, Jewett HJ, Walsh PC: Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol 127:704–706, 1982.PubMedGoogle Scholar
  140. 54.
    Taylor WJ, Richardson RG, Hafermann MD: Radiation therapy for localized prostate cancer. Cancer 43:1123–1127, 1979.PubMedCrossRefGoogle Scholar
  141. 55.
    Taylor I, Rowling J, West C: Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg 66:833–837, 1979.PubMedCrossRefGoogle Scholar
  142. 56.
    Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norm T: Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088–2098, 1978.PubMedCrossRefGoogle Scholar
  143. 57.
    Kadmon D, Heston WDW, Fair WR: Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 127:1238–1242, 1982.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Joseph R. Drago
  • Jack S. Elder

There are no affiliations available

Personalised recommendations